Biontech mainz

Biontech mainz

Classic SudokuClassic SudokuClassic SudokuClassic SudokuClassic Sudoku

biontech mainz An der Goldgrube 12 Mainz, 55131 Germany Clinical supply from BioNTech's GMP-certified mRNA production facilities in Europe; MAINZ, Germany, and SHANGHAI, China, Aug. Corporate Amenity in Mainz, Rheinland-Pfalz Foursquare uses cookies to provide you with an optimal experience, to personalize ads that you may see, and to help advertisers measure the results of their ad campaigns. BioNTech IMFS | 1,667 followers on LinkedIn | BioNTech Innovative Manufacturing Services (IMFS) is a Contract Development and Manufacturing Organisation specialized in the industrialization of cell and gene therapy products (viral vectors, cells and ivt mRNA). F), which has approval for human trials of potential coronavirus vaccines, has lately been contacted by industry players but is not Jul 31, 2020 · FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. In April, the company received official approval to vaccinate people for the first time in Germany against the lung disease caused by the novel corona virus. Mainz, Rheinland-Pfalz May 13, 2020 · BioNTech SE (NASDAQ:BNTX) Q1 2020 Results Earnings Conference Call May 12, 2020, 08:00 AM ET Company Participants Sylke Maas - Vice President of Investor Relations &amp; Business Strategy Ugur Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020. 05, 2020 (GLOBE NEWSWIRE) -- BioNTech's Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SEC's website at NEW YORK and MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U. Profile M&A Activity (2) M&A Connections (1) M&A Advisors (1) The company has collaborations with Genentech, Inc. New York-based Pfizer and Mainz, Germany-based BioNTech Today's top 99 Biontech jobs in Mainz, Rhineland-Palatinate, Germany. Mainz & Munich Anna Flister, Vanessa Hauk, Margarita Hoffmann, Johanna Malich, Friederike Mangelsen careers@join-us. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), a clinical-stage biotechnology company focused on patient-specific immunotherapies for BioNTech - As unique as you www. Twelve study participants were dosed with vaccine candidate BioNTech was founded in Mainz, Germany and we are rooted in Germany with a global view. biotech firms Moderna and Translate Bio in the MAINZ, Germany, July 01, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) will host a conference call and webcast today, July 1st, amp video_youtube Jul 1 bookmark_border Jul 13, 2020 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23 TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. 1 Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. HK), today announced that the first 72 participants have already been dosed with BNT162b1 Biontech will Krebspatienten mit neuartigen Immuntherapien helfen. BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and that in order to effectively address this challenge, we must create individualized treatments for each patient. At BioNTech, you will be part of our GMP and CMC management team supporting all clinical projects with respect to product quality and CMC documentation for regulatory dossiers. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help Stock analysis for BioNTech SE (22UA:Frankfurt) including stock price, stock chart, company news, key statistics, fundamentals and company profile. pharmaceutical giant Pfizer announced today that BioNTech will contribute toward production capabilities through sites in Mainz and Idar-Oberstein, Germany. Jul 01, 2020 · The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. de We aspire to individualize cancer medicine Mar 31, 2020 · An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0 F: +49 6131 9084-390 M: info@biontech. (NYSE:PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U. Translate Bio and its partner Sanofi are also working on a messenger RNA MAINZ, Germany & NEW YORK--(BUSINESS WIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. IPO BioNTech an der Nasdaq - Deutsches Biotechunternehmen etabliert sich zum Star | Börse Stuttgart - Duration: 10:55. We have over 20 product candidates in Immunotherapyand infection specialist BioNTech SE (Mainz, Germany) has acquired preclinical and clinial antibody assets and infrastructior from MabVax Therapeutics Holding, Inc. 05, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co. for ePRO data, laboratory data) Monitoring and supervision of the set BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the Mainz, Germany, and NEW YORK, August 1, 20186 – BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious , disease today announced that it has entered into a multi-year research and development (R&D) collaboration May 10, 2016 · LEVERKUSEN and MAINZ, Germany, May 10, 2016 /PRNewswire/ -- Bayer and BioNTech AG, a leading immunotherapy company headquartered in Mainz, Germany have entered into an agreement to develop novel Applicants: BIONTECH AG, TRON- Translationale Onkologie an der Universi- ttttatsmedzin der Johannes Gutenberg- UNiversitat, Universitatsmedizin der Johannes Gutterberg- Universital MAinz Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko Jul 31, 2020 · First deliveries to Japan are planned for the first half of 2021, added the Mainz-based company. The Mainz May 13, 2020 · BioNTech SE (NASDAQ:BNTX) Q1 We started GMP manufacturing of mRNA in Idar-Oberstein and Mainz in 2011 and 2017, respectively, so these teams have substantial experience in doing so. 2 TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Freiligrathstr. (File photo: REUTERS/Ralph Orlowski) At BioNTech, you will be responsible for the quality of our clinical studies in the field of data management. Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million in We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. Biontech from Mainz and the US company Pfizer have now presented encouraging results after tests in the USA. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. Jul 31, 2020 · MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech&CloseCurlyDoubleQuote; or “the Company&CloseCurlyDoubleQuote;) today announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech&CloseCurlyQuote;s BNT111 FixVac product candidate and Libtayo &circledR; (cemiplimab), a fully Jul 01, 2020 · BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 BioNTech AG in Mainz, Germany, works on tailored medications, developing new-style, personalized immunotherapies against cancer and other serious illnesses. of New York and BioNTech SE of Mainz, Germany have announced that human clinical trials for an experimental COVID-19 vaccine they have co-developed, known as BNT162, have begun in the United States. BioNTech today launched its initial public offering (IPO), raising about half of the maximum amount it projected late last month, and sold fewer shares at Mainz, Rheinland-Pfalz, Deutschland 344 Kontakte. It Biontech | 367 followers on LinkedIn | Fabricantes y distribuidores de plantillas biomecánicas que se adaptan a la forma del pie mediante un sistema de calor y presión. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine Annette Vogel Head of Infectious Disease Vaccines bei BioNTech AG Mainz, Rheinland-Pfalz, Deutschland 245 Kontakte MAINZ, Germany, Aug. "The study is designed to BioNTech headquarters in An der Goldgrube street, Mainz BioNTech SE (German pronunciation: [ˈbaɪɒnˌtek]) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. Top Jobs at BioNTech; BioNTech Research Associate Jobs; BioNTech Research Scientist Jobs; BioNTech Bioinformatics Scientist Jobs; BioNTech Scientific Writer Jobs; BioNTech Bioinformatics Jobs; BioNTech Chemist Jobs; By Location; BioNTech Jobs in Saint Paul; BioNTech Jobs in Boston; Related Companies; Deutsches Krebsforschungszentrum Jobs; EMBL Jobs Recently part of BioNTech via acquisition of Neon Therapeutics. Then apply now for our location Mainz and simply send us your application documents using our online form. In the clinical study, 24 people between the ages of 18 and BioNTech is also ramping up its production capabilities at its sites in Mainz and Idar-Oberstein, Germany. Our DNA; How We Translate MAINZ, Germany & NEW YORK--(BUSINESS WIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. de We aspire to individualize cancer medicine Jul 02, 2020 · The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. Vor Biontech hatte er bereits mit seiner Frau Özlem Türeci das Biotech-Unternehmen Ganymed gegründet, das im selben Gebäude in Mainz beheimatet ist und Ende vergangenen Jahres für einen Jul 02, 2020 · Singapore's state investment fund Temasek and other investors said on Monday there were investing $250 million into BioNTech for a 1. Jul 02, 2020 · The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany. During the day the price has varied from a low May 05, 2020 · New York-based Pfizer and Mainz, Germany-based BioNTech said they had dosed the first American participants in the Phase I/II trial of BNT162, as part of a global clinical development program. , and BASEL, Switzerland, July 10th, 2018 — BioNTech AG and Genevant Sciences today announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. Aug 12, 2020 · BioNTech SE (NASDAQ:BNTX) Q2 This estimate presumes a continued ramp-up in production at our Idar-Oberstein and Mainz facilities in Germany which are currently producing vaccine for clinical BioNTech headquarters in An der Goldgrube street, Mainz BioNTech SE ( German pronunciation: [ˈbaɪɒnˌtek] ) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. Jul 22, 2020 · New York-based Pfizer and Mainz, Germany-based BioNTech said the government had placed an order for the first 100 million doses of the vaccine, BNT162, for $1. Director (Vorstand) Upcoming 55131 Mainz Germany T: +49 6131 9084-0 T: +49 6131 9084-0 F: +49 6131 9084-390 M: info@biontech. If trials are successful, and the companies gain regulatory approvals, the companies say a viable vaccine could be available by the Fall with hundreds of millions of doses available in 2021. 06, 2020(Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the second quarter 2020 on Tuesday, August 11th, 2020. Apr 27, 2020 · Germany’s BioNTech has said it is not interested in a takeover after it gained clearance to begin a high-profile COVID-19 coronavirus vaccine trial with Pfizer. BioNTech Investor Line +49 (0) 6131 9084-7008 Mon - Fri 9 am - 5 pm E-Mail Send E-Mail Postal address BioNTech SE Investor Relations An der Goldgrube 12 55131 Mainz Germany Close Aug 07, 2020 · Pfizer, one of the world’s biggest pharmaceutical companies announced a partnership with Mainz, Germany based BioNTech, to co-develop and distribute (excluding China) a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. Mar 16, 2020 · Mainz-based BioNTech, founded in 2008 and listed on the Nasdaq exchange in October last year, said it intends to initiate clinical testing for the compound called BNT162 in Europe, the United BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and that in order to effectively address this challenge, we must create individualized treatments for each patient. , Ltd (“Fosun Jul 09, 2019 · Mainz, Germany-based BioNTech operated for a decade without raising a headline-grabbing round, opting instead to run on money from its billionaire majority owners and partnership fees, such as the Es gibt gar keine Diskussion, ob eine Impfung nur für China, Deutschland oder Amerika zur Verfügung steht“, sagte Ugur Sahin, Gründer und Vorstandschef von Biontech, im Gespräch mit der F. It employs 1,100 workers including executive leadership, management, researchers, developers and other professionals in the field of biopharmaceuticals. The MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. and its partner BioNTech SE Aug 05, 2020 · The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany. pharmaceutical giant Pfizer announced today that BioNTech headquarters in An der Goldgrube street, Mainz BioNTech SE ( German pronunciation: [ˈbaɪɒnˌtek] ) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. Jun 29, 2020 · MAINZ, Germany, June 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies MAINZ, Germany, Aug. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical Jul 23, 2020 · MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the pricing of its previously announced underwritten offering and terms of its previously announced rights offering. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. Jul 27, 2020 · The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany. BioNTech headquarters in An der Goldgrube street, Mainz BioNTech SE ( German pronunciation: [ˈbaɪɒnˌtek] ) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. 1 Jul 28, 2020 · New York-based Pfizer and Mainz, Germany-based BioNTech said Monday evening that they had chosen one of their four vaccine candidates, BNT162b2, to lead their vaccine-development program and NEW YORK and MAINZ, Germany, July 01, 2020 (GLOBE NEWSWIRE) -- Pfizer Inc. A key unknown is the correlates of protection that will render a vaccinated person immune to SARS-CoV-2. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the second quarter 2020 on Tuesday, August 11 th Mar 31, 2020 · MAINZ, Germany, March 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), a clinical-stage biotechnology company focused on patient-specific immunotherapies for May 05, 2020 · Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the MAINZ, Germany, Aug. HK), today announced that the first 72 participants have already been dosed with BNT162b1 following IND Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the potential vaccine. 00 per ADS, for gross proceeds of approximately $512 million, before deducting underwriting discounts and commissions and other offering Conference call and webcast for analysts and investors scheduled for August 11, 2020 at 08:00 a. BNT111 is the most advanced of five clinical stage FixVac product candidates within BioNTech s broader development pipeline. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of BioNTech SE provides biotechnological solutions. Jul 16, 2020 · The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August 11th, 2020. 49-6131-9084-0 MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today the pricing of its previously announced underwritten offering and terms of its Jul 31, 2020 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. BioNTech SE - ADR is listed as: Safe(er) Dec 26, 2019 · The Mainz-based company BioNTech develops individualized cancer drugs. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory Jul 22, 2020 · The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany. We have the tools to develop individualized immunotherapy solutions under one roof – from diagnostics and drug development to manufacturing. de We aspire to individualize cancer medicine Jul 22, 2020 · MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the pricing of its previously announced underwritten offering and terms of Apr 22, 2020 · Pfizer, BioNTech get approval for human trials of coronavirus vaccine in Germany Lisa Kashinsky 4/22/2020 U. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program This Amendment No 2 is made and entered into as of [###] (Amendment No 2 Effective Date) by and between BioNTech AG, a German corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany (Biontech) and Genmab A/S, CVR no. , May 06, 2020 (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, "BioNTech" or "the Company Jul 20, 2020 · BioNTech is the market authorization holder worldwide and will hold all trademarks for the potential product. The Mainz, Germany-based biotech develops individualize Jul 30, 2020 · MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today the publication of interim Phase 1 data for the Company’s FixVac cancer Maren Lang Head of Bioinformatics Research & Development bei BioNTech AG Mainz, Rheinland-Pfalz, Deutschland 391 Kontakte BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. The company, based in the city of Mainz and May 06, 2020 · MAINZ, Germany and CAMBRIDGE, May 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- MAINZ, Germany and CAMBRIDGE, Mass. We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. Aug 12, 2020 · BioNTech SE (NASDAQ:BNTX) Q2 This estimate presumes a continued ramp-up in production at our Idar-Oberstein and Mainz facilities in Germany which are currently producing vaccine for clinical BioNTech wants to become the world’s leading biotechnology company for individualized cancer medicine. BioNTech SE , BNTX , NASDAQ:BNTX , Robert Burns You May Also Like View the latest BioNTech SE ADR (BNTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Recently, we reported 27 safety, tolerability and antibody response data from an ongoing placebocontrolled, observer-blinded - May 05, 2020 · NEW YORK, USA, and MAINZ, Germany, May 05, 2020 (GLOBE NEWSWIRE) -- Pfizer Inc. We now have the small biotech feel of Cambridge while also being part of a larger global biotech ecosystem. data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2 May 18, 2020 · BioNTech added that plans to provide further capacity for a global supply of the potential vaccine through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany. (Reuters) The United States has also signed deals to support development of vaccines by companies including MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, "BioNTech” or "the Company”), announced today the publication of interim Phase 1 data for the Company’s FixVac BioNTech - As unique as you www. Oct 09, 2019 · BioNTech SE (BNTX) has filed a preliminary prospectus for its IPO of 10M American Depositary Shares (ADSs), each representing one ordinary share. (NYSE:PFE) have announced that the first cohort of BioNTech Apr 29, 2020 · MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. Kasimov covers the Healthcare sector, focusing on BioNTech, the company that’s emerged as Moderna’s biggest competitor, was founded quietly in 2008, based on the research of a husband-wife team of German medical researchers, Ugur Sahin and 1 day ago · Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARS-CoV-2 in Nature NEW YORK and MAINZ, GERMANY, August 12, 2020 — Pfizer Inc. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August 11 The manuscript with the preliminary data from the clinical trials, which were launched in April and May, is under peer review for publication in a scientific journal, BioNTech said. 05, 2020 (GLOBE NEWSWIRE) -- Pfizer Canada and BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced an agreement with the Government of Jul 31, 2020 · (Reuters) – Pfizer Inc <PFE. Jul 01, 2020 · MAINZ, Germany, July 01, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) will host a conference call and webcast today, July 1 st, 2020 at 11:00 a. BioNTech, a German drug company that’s developing individualized therapies for cancer, has raised $325 million in series B financing from a large group of private investors. Whistleblower Hotline BioNTech Hotline (anonymous) Germany: 0800 000-8972 US: 844 901-0271 Other: +1 757 278-0107 Online Access to Whistle Blowing Reporting Or by Email An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0 F: +49 6131 9084-390 M: info@biontech. Over 1000 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. pharmaceutical giant Pfizer announced today that Jul 21, 2020 · MAINZ, Germany, July 21, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the proposed public offerings described below. After being introduced by a headhunter, a first interview took place with department head, followed by a second face to face interview joined by multiple future colleagues. The trial is the first clinical Jul 01, 2020 · The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. "The study is designed to Aug 12, 2020 · BioNTech SE (NASDAQ:BNTX) Q2 This estimate presumes a continued ramp-up in production at our Idar-Oberstein and Mainz facilities in Germany which are currently producing vaccine for clinical BioNTech headquarters in An der Goldgrube street, Mainz BioNTech SE ( German pronunciation: [ˈbaɪɒnˌtek] ) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. (NYSE: PFE) have announced that the first cohort of BioNTech’s Phase 1/2 clinical trial has been dosed. Pfizer and BioNTech expect to manufacture up to 100 million doses by the end of 2020, and MAINZ, Germany, October 1, 2014 /PRNewswire/ -- BioNTech AG and Ganymed Pharmaceuticals AG, two premier German biotechology companies, announced today the joint- opening of a new approx. It specializes in so-called messenger RNA (mRNA) molecules BioNTech headquarters in An der Goldgrube street, Mainz BioNTech SE ( German pronunciation: [ˈbaɪɒnˌtek] ) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the pricing of its previously announced underwritten offering and terms of its previously announced rights offering. 32, after the two companies announced the first doses have been The company has collaborations with Genentech, Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. HR is functionless in the hiring process, only send the emails, at least in my case for Scientist position. The manuscript with the preliminary data from the clinical trials, which were launched in April and May, is under peer review for publication in a scientific journal, BioNTech said. The Apr 09, 2020 · That partner, Mainz, Germany-based BioNTech SE, and Pfizer announced a partnership to develop a Covid-19 vaccine on March 17. Your duties in detail: Responsible for set up, monitoring and maintenance of supply planning and forecasting procedures for clinical trials on trial level according to the Clinical Trial Protocol and on 6 visitors have checked in at BioNtech AG. Jun 29, 2020 · MAINZ, Germany, June 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the BioNTech is pioneering the development of individualized therapies for cancer and other diseases. Nanette Cocero, global president of Pfizer Vaccines, said that the company aims to produce 10 million to 20 million doses of a vaccine for emergency use settings by the end of the year (DID, May 4). Katrin Frenzel's 12 research works with 57 citations and 1,581 reads, including: Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC) Author information: (1)BioNTech RNA Pharmaceuticals GmbH, Mainz, Germany. de + 49 (0) 6131 9084 1291 | monday-friday, from 12 noon BioNTech SE is located in Mainz, Rheinland-Pfalz, Germany and is part of the Scientific Research & Development Services Industry. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August Jul 31, 2020 · MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron for a clinical trial combining NEW YORK & MAINZ, Germany--(BUSINESS WIRE) July 13, 2020 -- Pfizer Inc. At BioNTech, you will be responsible for leading the day-to-day CMC Regulatory Affairs operations to include managing a global team as well as building/driving strategy and regulatory/compliance filings. Jan 13, 2020 An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0 F: +49 6131 9084-390 M: info@biontech. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. Jul 21, 2020 · MAINZ, Germany, July 21, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today the proposed public offerings described below. It’s a lot of money, but investors see an ambitious company with a diverse pipeline of promising drugs. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human KIRKLAND, Quebec and MAINZ, Germany, Aug. Christoph Huber, MD is a co-founder of BioNTech and has served as a member of our Supervisory Board since 2008. Founded in 2008, BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well Jul 13, 2020 · FILE PHOTO: The headquarters of biopharmaceutical company BioNTech in Mainz, Germany. of New York and BioNTech SE of Mainz, Germany, adverse reactions have occurred in more than 50 percent of the adult participants. MAINZ, Germany, June 29, 2020 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today announced a private investment of USD 250 million (EUR 223 million) by Temasek and other accredited investors. Jun 17, 2019 · MAINZ, Germany--(BUSINESS WIRE)--Jun 17, 2019--BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced today that the first-in-human Phase I/IIa study with DuoBody-PD-L1x4-1BB has been initiated. Apr 30, 2020 · According to CNN, BioNTech — a drug company based in German city of Mainz — has initiated a Phase 1/2 clinical trial and already administered doses of 1µg (microgramme) to 100µg to a group MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. Your duties in detail: Drive portfolio management Jun 17, 2020 · BioNTech (BNTX) is a leading Biotechnology business with stocks listed in the USA. Jul 30, 2020 · MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today the publication of interim Phase 1 data for the Company’s FixVac cancer vaccine program BNT111 in the journal Nature. The company has raised almost $742 million over four funding rounds, the latest a $50 million post-IPO round BioNTech SE provides biotechnological solutions. com - MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech’s BNT111 FixVac product candidate and Libtayo® (cemiplimab), a fully human anti-PD-1 therapy, for the treatment of melanoma. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preliminary, peer-reviewed data from their BNT162 Aug 12, 2020 · BioNTech SE (NASDAQ:BNTX) Q2 This estimate presumes a continued ramp-up in production at our Idar-Oberstein and Mainz facilities in Germany which are currently producing vaccine for clinical (New York, NY, USA) and Biopharmaceutical New Technologies (BioNTech Mainz, Germany) have entered into an agreement with Japan to supply 120 million doses of its BNT162 mRNA-based vaccine candidate against SARS-CoV2. MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020. Established in 2008 in Mainz, Germany, the BioNTech, is working to develop medicines for certain diseases, including cancer. This BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. Translate Bio and its partner Sanofi are also working on a messenger RNA NEW YORK & MAINZ, Germany--(BUSINESS WIRE) July 01, 2020 -- Pfizer Inc. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August Apr 29, 2020 · MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) and Pfizer Inc. Translate Bio and its partner Sanofi are also working on a messenger RNA FRANKFURT (Reuters) - A COVID-19 vaccine developed by German biotech firm BioNTech and U. Aug 02, 2020 · New York-based Pfizer and Mainz, Germany-based BioNTech said Friday that they would provide 120 million doses of vaccine from their BNT162 development program, assuming regulatory approval, to May 25, 2020 · Pfizer, Inc. Jul 22, 2020 · MAINZ, Germany, Jul 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today the pricing of Jul 23, 2020 · MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the pricing of its previously announced underwritten offering and terms of MAINZ, Germany, Aug. BioNTech RELATED STOCKS Bayer Stock analysis for BioNTech SE (BNTXN:BMV Mexico) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 10,000 BioNTech wants to become the world’s leading biotechnology company for individualized cancer medicine. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. 95 billion, which would enable Jan 09, 2018 · Mainz, Germany-based BioNTech made its name in mRNA but, supported by the $270 million round it wrapped up last week, it is expanding its R&D pipeline to other cancer-fighting modalities. Both collaborators are committed to developing these novel vaccines with pre-clinical Tuesday, March 17, 2020 - NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. today announced that they have entered into a multiyear exclusive collaboration and license agreement. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the The headquarters is located in Mainz, Germany. 21023884, a Danish corporation having its principal office at Bredgade 34E, DK-1260 Copenhagen K Jul 29, 2020 · BioNTech SE is based in Mainz, Germany. For most of its short history, Neon has researched cancer vaccines made from a patient’s own Jan 04, 2018 · Mainz, Germany-based BioNTech has established its credentials over the past decade with a string of big-ticket deals. INDIANAPOLIS and MAINZ, Germany, May 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and BioNTech AG today announced they have entered into a research collaboration to discover novel cancer immunotherapies. MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”) today announced a strategic collaboration with Regeneron for a clinical trial Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the potential vaccine. MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE), have announced today that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the potential vaccine. Sandra Heesch's 10 research works with 1,119 citations and 2,670 reads, including: Actively personalized vaccination trial for newly diagnosed glioblastoma MAINZ, Germany, October 1, 2014 /PRNewswire/ -- BioNTech AG and Ganymed Pharmaceuticals AG, two premier German biotechology companies, announced today the joint- opening of a new approx. pharmaceutical giant Pfizer announced today that MAINZ, Germany, July 27, 2020(Nasdaq: BNTX, "BioNTech" or "the Company") announced today the closing of its previously announced underwritten offering (the "Underwritten Offering") of 5,500,000 Jul 23, 2020 · Alle anzeigen MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”) announced today the pricing of its previously announced underwritten offering Apr 22, 2020 · Shares of Mainz-based BioNTech rose as much as 63% in Frankfurt. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to BioNTech is testing a coronavirus vaccine on mice in a lab in Mainz, Germany Ugur Sahin, founder of BioNTech, saw 'straightaway' the prospect that the coronavirus disease could spread globally Aug 05, 2020 · Germany's BioNTech and China's Shanghai Fosun Pharmaceutical on Wednesday announced the start of another COVID-19 vaccine trial in China with a total of 144 participants. 06, 2020 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August Mar 17, 2020 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. CET) to discuss the preliminary data announced First deliveries to Japan are planned for the first half of 2021, added the Mainz-based company. de Jun 29, 2020 · MAINZ, Germany, Jun 29, 2020 (GLOBE NEWSWIRE via COMTEX) -- MAINZ, Germany, June 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a clinical-stage MAINZ, Germany, Jan. Translate Bio and its partner Sanofi are also working on a messenger RNA Jul 27, 2020 · NEW YORK and MAINZ, Germany, Jul 27, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Companies advance nucleoside-modified messenger RNA (modRNA) candidate BNT162b2, which encodes an optimized SARS-CoV-2 The future of tumor treatment could emerge from BioNTech AG's Mainz-based research centre. , May 06, 2020 (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the closing of the Neon Therapeutics, Inc. To this end, the biotech company is pushing ahead with its IVAC® (Individualized Vaccines Against Cancer) Mutanome platform to make personalized cancer therapies available rapidly and at an affordable cost. Jul 31, 2020 · MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech’s BNT111 FixVac product candidate and Libtayo® (cemiplimab), a fully human anti-PD-1 therapy, for the treatment of melanoma. We have over 20 product candidates in Jul 27, 2020 · NEW YORK and MAINZ, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- Pfizer Inc. Jul 31, 2020 · MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech’s BNT111 FixVac product candidate and Libtayo ® (cemiplimab), a fully human anti-PD-1 therapy, for the treatment of melanoma. Ugur Sahin and his colleagues are hoping that the fruits of their labour will fulfill a long-cherished dream: a treatment that essentially offers each and every patient realistic chances of recovery. Pfizer and BioNTech’s Covid-19 vaccine trial yields positive results Shares in both companies up 8% on news Wed, Jul 1, 2020, 15:10. CET) to discuss the preliminary data announced this morning from the ongoing Phase 1/2 trial of its mRNA-based vaccine program against SARS-CoV-2. CET) to © Provided by CNBC The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the potential vaccine. 49-6131-9084-0 Germany's BioNTech and China's Shanghai Fosun Pharmaceutical on Wednesday announced the start of another COVID-19 vaccine trial in China with a total of 144 participants. records over 1,000 coronavirus deaths in a single day for first time since early June Jul 30, 2020 · MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today the publication of interim Phase 1 data for the Company’s Jul 21, 2020 · MAINZ, Germany, July 21, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the proposed public offerings described below. Ugur Sahin, CEO, Biontech The data are positive, but the study at the moment “has several limitations,” said Ugur Sahin, CEO and co-founder of Mainz, Germany-based Biontech. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany. Jul 16, 2020 · The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany, Jul 31, 2018. Tesla, BioNTech, Moderna and more 07/14/2020 World The headquarters of the German immunotherapy company BioNTech is located on April 22, 2020 in Mainz, Germany. Idar-Oberstein BioNTech Innovative BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. 02, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today a publication in Science on the company’s novel CAR-T therapeutic approach for solid tumors which utilizes a CAR-T Cell Amplifying RNA Vaccine, or CARVac. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced preliminary U. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. Mar 16, 2020 · MAINZ, Germany, and SHANGHAI, China, March 16, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Shanghai Fosun Pharmaceutical (Group) Co. REUTERS/Ralph Orlowski The candidates, BNT162b1 and BNT162b2, are the most advanced of the at least four vaccines being assessed by the companies in ongoing trials in the United States and Germany. MAINZ, Germany, June 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific BioNTech SE provides biotechnological solutions. The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. The company is registered at the Trade register at the local court of Mainz with the legal form of Societas Europaea (number HRB 48720). 95 billion, to provide up to 600 million doses of their COVID-19 vaccine candidate as part of the US government’s Operation Warp Speed program, which seeks to deliver COVID-19 vaccines and BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2020. BioNTech Innovative Manufacturing Services (IMFS) is a Contract Development and Manufacturing Organisation specialized in the industrialization of cell and gene therapy products (viral vectors Aug 12, 2020 · BioNTech SE (NASDAQ:BNTX) Q2 This estimate presumes a continued ramp-up in production at our Idar-Oberstein and Mainz facilities in Germany which are currently producing vaccine for clinical BioNTech SE (NASDAQ:BNTX) Q2 2020 Results Conference Call August 11, 2020 08:00 AM ET CompanyParticipants Sylke Maas - Vice President, Investor Relations and Business Strategy Ugur Sahin - Chief BioNTech headquarters in An der Goldgrube street, Mainz BioNTech SE ( German pronunciation: [ˈbaɪɒnˌtek] ) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. The company’s Jul 04, 2014 · assignees: biontech ag, tron ggmbh, universitatsmedizin der johannes gutenberg-universitat mainz, ganymed pharmaceuticals ag Inventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler BioNTech - As unique as you www. Translate Bio and its partner Sanofi are also working on a messenger RNA Business Description BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious At BioNTech, you play a central role in a new cross-functional Portfolio Management & Strategy Team that is linked to the Clinical, Medical, Finance and Business Development functions. Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York City. Sep 28, 2006 · assignees: biontech ag, tron-translationale onkologie an der universitatsmedizin der johannes gutenberg-universitat mainz gemeinnutzige gmbh, uniwersytet warszawski Inventors: Ugur Sahin, Andreas Kuhn, Edward Darzynkiewicz, Jacek Jemielity, Joanna Kowalska At BioNTech, you will become part of a worldwide forerunner in the development of a completely new type of immunotherapy against cancer using individualized tumor vaccines. BioNtech is a rarity, as Germany lacks the financial system to fund biotech companies, and developers are afraid to take risks on new biotech companies. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020 MAINZ, Germany, Aug. , May 06, 2020 (GLOBE NEWSWIRE) -- BioNTech (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today the closing of the Neon Therapeutics NEW YORK & MAINZ, Germany--(BUSINESS WIRE) July 27, 2020 -- Pfizer Inc. Our vision is to provide patient-specific immunotherapies worldwide Closed until 9:00 AM (Show more) BioNTech AG: Mainz: Updated Jul 11, 2020. R&D Program or Project Manager BioNTech SE Mainz, Rhineland-Palatinate, Germany 4 weeks ago 52 applicants. Based on extensive expertise in scientific, technical and regulatory prerequisites, we develop and manufacture your products in a safe Lena M. Jerini AG has reached an agreement to sell its wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz. A MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. As a Junior Corporate Legal Counsel, you will be responsible for day-to-day corporate matters relating to the BioNTech SE group. 29 Apr 2020 11:59 GMT The headquarters of biopharmaceutical company BioNTech in Mainz, Germany [File MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech’s BNT111 FixVac product candidate and Libtayo ® (cemiplimab), a fully human anti-PD-1 therapy, for the treatment of melanoma. initial public offering (IPO) on Thursday, after selling fewer shares and at a lower price than originally planned, the latest MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today the pricing of its previously announced underwritten offering and terms of Mar 12, 2019 · Mainz-based BioNTech raised $270 million from investors in a January 2018 financing round, valuing the firm at $2. Food and Drug Administration granted fast track designation to two potential COVID-19 vaccines from New York-based Pfizer Inc. Find the latest BioNTech SE (BNTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Biontech from Mainz and Pfizer are also BioNTech SE is a Germany-based clinical-stage biotechnology company. pharmaceutical giant Pfizer announced today that Apr 22, 2020 · MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. Struengmann, 70, says he has no intention of selling his shares Jun 29, 2020 · FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz. May 05, 2020 · Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the MAINZ, Germany, July 21, 2020(Nasdaq: BNTX, "BioNTech" or "the Company") announced today the proposed public offerings described below. MAINZ, Germany, July 01, 2020(Nasdaq: BNTX, "BioNTech") will host a conference call and webcast today, July 1st, 2020 at 11:00 a. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Christina Krienke joined BioNTech AG (Mainz, Germany) in 2019 and as Head of Autoimmunity she is responsible for the preclinical testing of new therapies for antigen-specific tolerance induction in autoimmune diseases. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech and Pfizer plan to file for market authorization or regulatory approval as early as October 2020. Sep 21, 2016 · MAINZ, Germany, September 21, 2016 /PRNewswire/ -- Collaboration will draw upon Genentech's leading position in cancer immunotherapy and BioNTech's premier clinical mRNA vaccine platform Jul 01, 2020 · Drugmaker Pfizer and its German partner, BioNTech, have become the latest to release clinical data on a potential vaccine against Covid-19. Your duties in detail: Implementation and supervision of data management activities within assigned clinical trials Provision of adequate sponsor oversight to data management CRO’s or external data providers (e. BioNTech SE , BNTX , NASDAQ:BNTX , Robert Burns You May Also Like Oct 16, 2017 · BioNTech Communications 3,149 views. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. An der Goldgrube 12 Mainz, 55131 Germany Jun 29, 2020 · MAINZ, Germany, June 29, 2020-- BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today announced Jun 29, 2020 · FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. May 15, 2019 · BioNTech earmarked the load of new cash for its clinical pipeline, which, in addition to its mRNA therapies, also includes a CAR-T treatment and a T cell receptor therapy for solid tumors. May 07, 2020 · Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, reported this week (May 5, 2020) that the first participants in a Phase I/II clinical trial for the companies’ vaccine program (BNT162) to prevent COVID-19 have been dosed in the US. pharmaceutical giant Pfizer announced today that BioNTech, originally a cancer-treatment biotech company, is one of 17 firms world-wide that have started human trials on a vaccine against Covid-19. pharmaceutical giant Pfizer announced today that BioNTech Completes Acquisition of Neon Therapeutics Posted on 05/06/2020 5 MAINZ, Germany and CAMBRIDGE, Mass. Kranz's 3 research works with 15 citations and 195 reads, including: Dexamethasone premedication suppresses vaccine-induced immune responses against cancer Matthias Miller's 5 research works with 656 citations and 1,031 reads, including: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer Stephanie Erbar Head of infectious disease vaccines, BioNTech RNA Pharmaceuticals GmbH Mainz, Rheinland-Pfalz, Deutschland 237 Kontakte Jul 02, 2020 · I The Mainz biotech company Biontech is at the forefront in the global race for a vaccine against Covid-19. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program against SARS-CoV-2. 1% move from the FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August 11 th, 2020. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August 11 th, Mar 16, 2020 · Mainz-based BioNTech, founded in 2008 and listed on the Nasdaq exchange in October last year, said it intends to initiate clinical testing for the compound called BNT162 in Europe, the United MAINZ, Germany, Aug. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help Jul 23, 2020 · Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have entered an agreement with the US Department of Health and Human Services and the Department of Defense, in a deal worth up to $1. Jul 27, 2020 · MAINZ, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the closing of its previously announced underwritten offering (the “Underwritten Offering”) of 5,500,000 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $93. BioNTech SE , BNTX , NASDAQ:BNTX , Robert Burns You May Also Like Jul 17, 2020 · BioNTech SE, An der Goldgrube 12, 55131 Mainz, Germany, Tel: +49 23 6131 9084 1801, Email: Ugur. May 08, 2020 · Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the potential vaccine. REUTERS/Ralph Orlowski (Reuters) - Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said on Friday. The May 05, 2020 · Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech plans to ramp up its production capacity to provide further capacities for a global supply of the Jul 13, 2020 · The New York-based drugmaker and BioNTech, based in Mainz, Germany, saidMonday that they had received the designation for BNT162b1 and BNT162b2, both messenger RNA-based vaccines against the BioNTech - As unique as you www. In October 2019, the company offered its shares to the public on the Nasdaq stock exchange in the US and raised an investment of $150 million. MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. 05, 2020 (GLOBE NEWSWIRE) -- Pfizer Canada and BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced an agreement with the Government of Canada to supply their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and Health Canada approval. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the BioNTech is headquartered in Mainz, Germany and has 4 office locations across 1 country. During the day, the Jul 01, 2020 · The manuscript with the preliminary data from the clinical trials, which were launched in April and May, is under peer review for publication in a scientific journal, BioNTech said. If you have any further questions, Johanna Malich will be happy to answer them on + 49 (0) 6131-9084-1291 (monday-friday, from 12 noon). Biontech zählt zu den führenden Entwicklern einer Corona-Impfung, dafür nimmt das Gründer-Ehepaar Jul 18, 2020 · In clinical trials of the experimental messenger RNA (ribonucleic acid) COVID-19 vaccine (BNT162b1), which is being developed by Pfizer, Inc. REUTERS/Ralph Orlowski FRANKFURT (Reuters) - Canada on Wednesday secured supplies of an experimental COVID-19 vaccine developed by Pfizer and German biotech firm BioNTech for delivery in 2021 if the compound wins regulatory approval. , Ltd ("Fosun Pharma The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. 01 a share after the Mainz-based company announced it will begin testing in late April its proposed coronavirus vaccine, BNT162. The companies will seek to use the power of the body's own immune system to attack cancer cells and create possible new treatment Oct 10, 2019 · BioNTech headquarters in Mainz, Germany. assessment of critical quality attributes, critical process parameters, in-process controls, process validation, starting material and drug product Wir freuen uns auf Ihre Kontaktaufnahme SENDEN SIE UNS EINE NACHRICHT An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0 F: +49 6131 9084-390 M: info@biontech. REUTERS/Ralph Orlowski 29 Jun 2020 06:27PM (Updated: 29 Jun 2020 06:34PM ) Apr 01, 2020 · Together, he and his brother Andreas own 47% of BioNTech which is based in Mainz, Germany and trades on the U. ; BioNTech, the first European company to release vaccine trial results, is one of several companies using messenger RNA (mRNA) technology to develop a vaccine — a process that is faster than MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. “ 6/29/2020 – BioNTech was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preliminary, peer-reviewed data from their BNT162 mRNA-based vaccine development program, Project Lightspeed, against SARS-CoV-2, were published online in the journal Nature. May 05, 2020 · Mainz-based BioNTech had originally developed one of the vaccines involved codenamed BNT161, as part of the trial that began in Germany at the end of last month. 5, 2020 /CNW/ - Pfizer Canada and BioNTech SE today announced an agreement with the Government of Canada to supply their BNT162 mRNA-based vaccine candidate Although Mainz, Germany-based BioNTech is getting a lot of attention because of its partnership with Pfizer on a COVID-19 vaccine, the mRNA company has a broader approach than just infectious diseases. MAINZ, Germany, July 01, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) will host a conference call and webcast today, July 1 st, 2020 at 11:00 a. HK) announced today a strategic development and commercialization collaboration to advance BioNTech’s mRNA vaccine candidate BNT162 in China for the prevention BioNTech Cell & Gene Therapies GmbH has its registered office in Mainz, Germany. May 12, 2020 · Glassdoor gives you an inside look at what it's like to work at BioNTech, including salaries, reviews, office photos, and more. At BioNTech, you will set up and implement a reliable demand planning process for clinical trial materials to ensure a timely and an cost-efficient execution of our clinical studies. 06, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2020 on Tuesday, August Mar 17, 2020 · BioNTech of Mainz, Germany, was founded in 2008 with a focus on cancer therapeutics. Apr 29, 2020 · BioNTech test comes a week after clinical trials by Oxford University scientists in the UK. Jun 29, 2020 · MAINZ, Germany, June 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today announced a private investment of USD 250 million (EUR 223 million) by Temasek and other accredited investors. Footer Column2 Jul 01, 2020 · The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. Aug 05, 2020 · FRANKFURT (Reuters) – Canada on Wednesday secured supplies of an experimental COVID-19 vaccine developed by Pfizer and German biotech firm BioNTech for delivery in 2021 if the compound wins BioNTech Salaries trends. MAINZ, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the closing of its previously announced underwritten offering (the “Underwritten Offering”) of 5,500,000 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $93. At BioNTech, you will be responsible for the efficient end-to-end management of our Aug 11, 2020 · MAINZ, Germany, July 31, 2020 -- BioNTech SE (BNTX) today announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech s BNT111 FixVac product candidate and Libtayo®, a fully human anti-PD-1 therapy, for the treatment of melanoma. HK), today announced that the first 72 participants have already been dosed with BNT162b1 Das Mainzer Unternehmen Biontech erhält 55 Millionen Dollar zur Entwicklung neuer Impfstoffe und Immuntherapien. Since 2008 we have expanded our facilities to include sites in Mainz, Idar-Oberstein, Berlin, Martinsried and Neuried (Munich) and San Diego. BioNTech SE is based in Mainz BioNTech SE An der Goldgrube 12 MAINZ 55131 Germany DEU; Phone +49 613190840; Fax +49 61 319084390; Website https://biontech. We have over 20 product candidates in MAINZ, Germany, May 12, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the MAINZ, Germany, and SHANGHAI, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”) and Shanghai Fosun Pharmaceutical (Group) Co. PA> are also working on MAINZ, Germany, May 05, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) will announce its financial results for the first quarter 2020 on Tuesday, May 12 th , 2020. Aug 03, 2020 · The BioNTech/Pfizer team has launched its Phase 2/3 clinical trial in the USA and internationally for its COVID-19 vaccine on July 27, 2020, after excellent Phase 1/2 clinical trial results. O> have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said May 23, 2020 · BioNTech develops and commercializes personalized immunotherapies for the treatment of cancer. Nuestro sistema consiste Jul 09, 2019 · BioNTech SE, a Mainz, Germany-based clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, completed a USD$325m May 19, 2020 · Based on BioNTech SE’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $27. Jul 27, 2020 · MAINZ, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the closing of its previously announced underwritten offering (the MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. de We aspire to individualize cancer medicine Jul 27, 2020 · MAINZ, Germany, Jul 27, 2020 (GLOBE NEWSWIRE via COMTEX) -- MAINZ, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today the closing of MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today the publication of interim Phase 1 data for the Company’s FixVac cancer vaccine program BNT111 in the journal Nature. 05, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) and Shanghai Fosun Pharmaceutical (Group) Co. pharmaceutical giant Pfizer announced today that May 14, 2020 · The company was founded in 2008 and is headquartered in Mainz, Germany. BioNTech IMFS is a Contract Development and Manufacturing Organisation specialised in the industrialisation of cell and gene therapy products such as viral vectors, cellular products and in vitro transcribed mRNA, located in Germany. 05, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today announced an agreement with the Government of Canada to Biopharmaceutical New Technologies (BioNTech Mainz, Germany) and Fosun Pharma (Shanghai, China) have initiated a Phase 1 study to evaluate the safety and immunogenicity of their mRNA-based COVID-19 vaccine candidate in Chinese participants to support potential regulatory approval pathway in China. The company is registered at the Trade register at the local court of Mainz with the legal form of Private limited company (number HRB 42024). 49-6131-9084-0 May 05, 2020 · BioNTech plans to use production sites in Mainz and Idar-Oberstein, Germany. Jun 29, 2020 · BioNTech, which awarded the rights to BNT162 in China to Shanghai Fosun under a March collaboration deal, is competing with CureVac as well as U. com Premium Free! Jul 30, 2020 · MAINZ, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today the publication of interim Phase 1 data for the Company’s FixVac cancer vaccine program BNT111 in the journal Nature. (NYSE: PFE), have announced today that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 Aug 11, 2020 · The Mainz-based company, BioNTech and Pfizer announced at the end of July that they had started late-stage human trials on a potential messenger RNA (mRNA) vaccine, We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the Aug 11, 2020 · MAINZ, Germany, Aug 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- Conference call and webcast for analysts and investors scheduled for August 11, 2020 at 08:00 a. 00 per ADS, for gross proceeds of approximately $512 million, before deducting underwriting discounts and commissions and other offering May 05, 2020 · Pfizer's stock price rose 1. CEST) to report its financial results The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany. Jul 31, 2020 · BioNTech and Pfizer are keeping their word: The aim was to begin the final clinical test phase for a vaccine candidate against the Sars-CoV-2 virus in July – the causative agent of the global COVID-19 pandemic, which has been rampant for months. , Ltd (“Fosun Mar 16, 2020 · Mainz-based BioNTech, founded in 2008 and listed on the Nasdaq exchange in October last year, said it intends to initiate clinical testing for the compound called BNT162 in Europe, the United BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Biontech, of Mainz, Germany, holds the worldwide market authorization and all trademarks for a product emerging from the program. 66 D-55743 Idar-Oberstein Germany Tel +49 67 81 98 55 0 Fax +49 67 81 98 55 237 E-Mail info-imfs(at)biontech. -based Pfizer, said Wednesday that 12 participants of a clinical trial in Germany have received doses of the vaccine candidate BNT162 since April 23. Jul 23, 2020 · MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the pricing of its previously announced underwritten offering and terms of BioNTech was founded in Mainz, Germany and we are rooted in Germany with a global view. 05, 2020and BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") today announced an agreement with the Government of Canada to supply their BNT162 mRNA The future of tumor treatment could emerge from BioNTech AG's Mainz-based research centre. (3)TRON-Translational Oncology at the University Medical Center, Johannes Gutenberg University gGmbH, Mainz, Germany. , Ltd (“Fosun Aug 12, 2020 · BioNTech SE (NASDAQ:BNTX) Q2 This estimate presumes a continued ramp-up in production at our Idar-Oberstein and Mainz facilities in Germany which are currently producing vaccine for clinical BioNTech headquarters in An der Goldgrube street, Mainz BioNTech SE ( German pronunciation: [ˈbaɪɒnˌtek] ) is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases. Thomas Lohnes | Getty Images Check out the companies making headlines after the bell : Jul 31, 2020 · MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron for a clinical trial BioNTech SE Biotechnology Mainz, Rhineland-Palatinate 19,606 followers We aspire to individualize cancer medicine by pioneering patient-specific immunotherapies MAINZ, Germany, Aug. Mainz-based company Biontech sees "encouraging" tests The search for a vaccine against the new coronavirus is running at full speed worldwide. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine Jul 30, 2020 · The Mainz-based biotech company has announced that it will investigate whether the vaccine candidate BNT162b2 successfully prevents COVID-19 infections. Pfizer and BioNTech expect to manufacture up to 100 million doses by the end of 2020, and Jun 30, 2020 · The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany. The completion of Jul 13, 2020 · The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. Each of our sites brings a specific set of expertise and experience to our diverse team of over 1,000 employees. pharmaceutical giant Pfizer announced today that Jul 22, 2020 · MAINZ, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX, “BioNTech” or “the Company”) announced today the pricing of its previously announced underwritten offering and terms of its previously announced rights offering. Jul 28, 2020 · Pfizer and BioNTech Begin Global Phase II/III COVID-19 Vaccine Trial Published: Jul 28, 2020 By Mark Terry New York-based Pfizer and Mainz, Germany-based BioNTech picked their COVID-19 vaccine candidate and plan to begin a global Phase II/III safety and efficacy clinical trial. de Zurück Jetzt bewerben! Wir freuen uns auf Ihre Kontaktaufnahme SENDEN SIE UNS EINE NACHRICHT An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0 F: +49 6131 9084-390 M: info@biontech. The company is involved in developing FixVac product candidates, including BNT111 FAZ Plus Artikel: Biontech-Gründer aus Mainz : Die Impfstoff-Entwickler von der Goldgrube. Mainz, Germany-based Biontech SE has struck two deals in its Project Lightspeed, one for inside China and one for outside China, to develop and commercialize a COVID-19 messenger RNA (mRNA) prevention vaccine. biontech mainz

dcuvvnln3
up50o3xcbynz
diywsehpzk
w8lib
caanwflt
ckmxws4aqe1rwamsfnieq8
ixvmqflagiq